TY - JOUR
T1 - Pseudo-obstruction in the critically ill
AU - Delgado-Aros, Silvia
AU - Camilleri, Michael
N1 - Funding Information:
Dr Camilleri is supported by grants #R01-DK54681 and #K24-DK02638 from the National Institutes of Health. We thank Ms Cindy Stanislav for her secretarial support.
PY - 2003/6
Y1 - 2003/6
N2 - Intestinal pseudo-obstruction is defined as a clinical syndrome characterized by impairment of intestinal propulsion, which may resemble intestinal obstruction, in the absence of a mechanical cause. It may involve the small and/or the large bowel, and may present in acute, subacute or chronic forms. We have performed a systematic review of acute pseudo-obstruction, also referred to as Ogilvie's syndrome in the literature, and focused on proposed mechanisms, manifestations and management of post-surgery and critically ill patients who suffer from one or more underlying clinical conditions. The hallmark of the syndrome is massive intestinal distension, which is detected on clinical inspection and plain abdominal radiography. The underlying pathophysiological mechanisms are not fully understood. Therefore, treatment focuses on preventing intestinal perforation, which is associated with an average 21% mortality rate.
AB - Intestinal pseudo-obstruction is defined as a clinical syndrome characterized by impairment of intestinal propulsion, which may resemble intestinal obstruction, in the absence of a mechanical cause. It may involve the small and/or the large bowel, and may present in acute, subacute or chronic forms. We have performed a systematic review of acute pseudo-obstruction, also referred to as Ogilvie's syndrome in the literature, and focused on proposed mechanisms, manifestations and management of post-surgery and critically ill patients who suffer from one or more underlying clinical conditions. The hallmark of the syndrome is massive intestinal distension, which is detected on clinical inspection and plain abdominal radiography. The underlying pathophysiological mechanisms are not fully understood. Therefore, treatment focuses on preventing intestinal perforation, which is associated with an average 21% mortality rate.
KW - ADL 8-2698
KW - Ileus
KW - Neostigmine
KW - Ogilvie
KW - Pseudo-obstruction
UR - http://www.scopus.com/inward/record.url?scp=0141687270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141687270&partnerID=8YFLogxK
U2 - 10.1016/S1521-6918(03)00023-4
DO - 10.1016/S1521-6918(03)00023-4
M3 - Article
C2 - 12763505
AN - SCOPUS:0141687270
SN - 1521-6918
VL - 17
SP - 427
EP - 444
JO - Bailliere's Best Practice and Research in Clinical Gastroenterology
JF - Bailliere's Best Practice and Research in Clinical Gastroenterology
IS - 3
ER -